Preclinical research on the trispecific antibody, ISB 2001, published in Nature Cancer leveraged virtual trials to select a higher starting dose…
Company welcomes additional late-stage expertise as it prepares for amezalpat pivotal studyBRISBANE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Tempest…
Results from triple combination of efti, radiotherapy and KEYTRUDA® (pembrolizumab) to be presented at the Connective Tissue Oncology Society 2024…
MyRisk®, FirstGene®, Prequel®, and Foresight® studies among 10 datasets to be shared by MyriadSALT LAKE CITY, Sept. 18, 2024 (GLOBE…
FDA has authorized the Expanded Access Policy (EAP) to help metastatic breast cancer patients in need for novel treatmentsExpanded access…
Company to present new data, highlighting progress in its therapeutics program for recurrent glioblastoma (rGBM)AUSTIN, Texas, Sept. 18, 2024 (GLOBE…
EU-GMP Certified Redecan Cannabis Now Available in Australia with Medical PrescriptionNEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Tilray Medical,…
Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks’ proprietary antibody-drug conjugate development platformsVANCOUVER,…
ImCheck Receives FDA Fast Track Designation for ICT01in Combination with Azacitidine and Venetoclaxin First-Line Acute Myeloid Leukemiafor Patients Unfit for Induction…
Hamilton, Bermuda, Sept. 17, 2024 (GLOBE NEWSWIRE) -- $4 million upfront with up to an additional $8 million of aggregate…